Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
July 9, 2020 - Ipsen Biopharmaceuticals announced the FDA approval of Dysport (abobotulinumtoxinA), for the treatment of spasticity in patients 2 years of age and older.
